Psychostimulant treatment of adults with mental retardation and attention-deficit hyperactivity disorder

Jou, Roger J.; Handen, Benjamin L.; Hardan, Antonio Y.

doi:10.1111/j.1440-1665.2004.02130.x

Cited by 6 publications

(4 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…All studies but one featured children/young people with ID and ADHD, with an age range of three to 18. One study [20] was done solely in adults (n = 10). Methylphenidate was the most researched drug; covered by 10 papers including two systematic reviews.…”

Section: Resultsmentioning

confidence: 99%

Clinical guidance on pharmacotherapy for the treatment of attention-deficit hyperactivity disorder (ADHD) for people with intellectual disability

Miller

Perera

Shankar

2020

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

Introduction: ADHD causes significant distress and functional impairment in multiple domains of daily life. Therefore, diagnosis and treatment are important to improve the quality of life of people. The pharmacotherapy for ADHD is well established but needs systematic evaluation in Intellectual Disability (ID) populations. Areas covered: This paper reviews the ADHD pharmacological treatment in people with ID using the PRISMA guidance for scoping reviews to help identify the nature and strength of evidence. Expert opinion: In the last 20 years, seven randomized controlled trials have evaluated pharmacotherapies for ADHD in people with ID; five looking at methylphenidate. Generally, studies were underpowered; all but two had less than 25 participants. Of the two larger trials one was single blinded and therefore open to bias. Only two used a parallel-group method, the remainder were mostly short crossover trials; not ideal when measuring behavioral and psychological parameters which are long standing. The remaining evidence is made up of observational studies. Methylphenidate and atomoxetine, particularly at higher doses, have shown clear benefits in people with ID. Most people with ID tolerated ADHD medications well. Benefits were seen in behavioral and/or cognitive domains. The evidence base is limited, though promising, for dexamfetamine, clonidine, and guanfacine.

show abstract

Section: Resultsmentioning

confidence: 99%

Clinical guidance on pharmacotherapy for the treatment of attention-deficit hyperactivity disorder (ADHD) for people with intellectual disability

Miller

Perera

Shankar

2020

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

show abstract

“…Le TDA/H peut également être un trouble comorbide et un diagnostic différentiel de la DI (APA, 2000;Brisson et al, 2012;Carr et al, 2007). À titre d'exemple, la prévalence du TDA/H en comorbidité avec la DI se retrouve -selon les ouvrages -de trois à cinq fois plus élevée que dans la population générale adulte (Carr et al, 2007) et s'observerait par la présence de « bougeotte » physique, « bougeotte » des idées, distractivité/inattention et irritabilité/impulsivité sans que cela ne soit diagnostiqué (Jou, Handen et Hardan, 2004). La coexistence de ce trouble avec une DI soulève la possibilité de déficits neurologiques majeurs (Griffiths et al, 2002).…”

Section: L'association On Intellectual and Developmental Disabilitiesunclassified

Étude descriptive de l’évaluation de comorbidité psychiatrique en déficience intellectuelle adulte

Brisson

Bolduc

Jourdan-Ionescu

2014

rfdi

View full text Add to dashboard Cite

Cet article exploratoire discute de l’apport de l’examen cognitif dans l’évaluation de comorbidité psychiatrique en déficience intellectuelle (DI), comme le trouble déficit de l’attention/hyperactivité (TDA/H). Treize adultes (deux avec DI et TDA/H en comorbidité et onze avec DI sans TDA/H) de l’Institut universitaire en santé mentale de Québec sont évalués sur dix domaines cognitifs. Les résultats sont en partie déficitaires, avec une variabilité intra-sujet. Malgré la petite taille de l’échantillon, les difficultés cognitives des participants adultes avec DI et TDA/H ne semblent pas plus importantes que celles de participants sans TDA/H. En conclusion, l’évaluation cognitive d’adultes DI apparaît pertinente qualitativement, mais discutable quantitativement. Les limites de cette étude exploratoire et les directions futures sont également discutées.This exploratory study reports on the contribution of cognitive assessment in the assessment of psychiatric comorbidity in intellectual disability (ID), such as the attention deficit disorder/ hyperactivity disorder (ADHD). Thirteen adults (two participants with comorbid ADHD and ID and eleven participants with ID without ADHD) from the Institut universitaire en santé mentale de Québec were assessed in ten cognitive domains. The results are partly deficient, with intra-subject variability. Although limited by the small sample size, the difficulties of participants with ADHD seem not to be more important from the difficulties of those without ADHD. In conclusion, the cognitive assessment of adults ID seems to be relevant qualitatively, but quantitatively questionable. The limitations of this exploratory study and future directions are also discussed

show abstract

“…ID children can't follow instructions, game rules, or role exchange. The percentage of children with ADHD among intellectually disabled children ranges between 9% and 18% (Jou et al, 2004).…”

Section: Introductionmentioning

confidence: 99%

Validity and Reliability of an Attention Deficit and Hyperactivity Disorder Measure for a Sample of Omani Children

Al-Qaryouti

Abu-Hilal

Mahmoud

2017

EJREP

View full text Add to dashboard Cite

Introduction. The purpose of this study was to develop and validate a diagnostic measure of attention deficit, hyperactivity disorder and impulsivity.Method. The instrument was administered to normal (n=51), learning disability (LD) (n=96), and intellectually disabled (ID) (n=108) children. The instrument in its final form comprises 36 items.Results. Reliability analysis, exploratory factor analysis, and confirmatory factor analysis revealed that the instrument possesses good reliability and validity estimates. MANOVA revealed that intellectually disabled, learning disabled and normal children differed significantly on all of the five subscales. The pattern of difference mainly favored I.D. children then L.D. The lowest scores on all of the subscales were those of the normal children.Discussion and Conclusion. It is important that children with L.D. be differentiated from other types of disabilities. The instrument at hand is presumed to make such distinction. Namely, the instrument is a tool to identify children with attention deficit and hyperactivity disorder.

show abstract

Psychostimulant treatment of adults with mental retardation and attention-deficit hyperactivity disorder

Abstract: Psychostimulants might be effective and well-tolerated in the treatment of ADHD in adults with MR. However, larger prospective open-label studies, and, eventually, double-blind placebo-controlled studies are needed to confirm these findings.

Cited by 6 publications

References 13 publications

Clinical guidance on pharmacotherapy for the treatment of attention-deficit hyperactivity disorder (ADHD) for people with intellectual disability

Clinical guidance on pharmacotherapy for the treatment of attention-deficit hyperactivity disorder (ADHD) for people with intellectual disability

Étude descriptive de l’évaluation de comorbidité psychiatrique en déficience intellectuelle adulte

Validity and Reliability of an Attention Deficit and Hyperactivity Disorder Measure for a Sample of Omani Children

Contact Info

Product

Resources

About